According to the news from Zhitong Finance APP, GLORIA PHARMA (002437.SZ) announced that its wholly-owned subsidiary Tianjin GLORIA Boda Technology Co., Ltd. (referred to as "Tianjin Boda") has signed a "Marketing Service Agreement" with Eisai (China) Pharmaceutical Co., Ltd. (referred to as "Eisai China Pharmaceutical") for "Mecobalamin Injection" (trade name: MicoCare).

According to the agreement, Eisai China Pharmaceutical authorizes Tianjin Boda to exclusively promote Mecobalamin Injection (trade name: MicoCare) in mainland China, with the authorization period starting from June 1, 2025, until the expiration of the agreement. Tianjin Boda is responsible for providing marketing services and other related services for the product in the aforementioned region. Eisai China Pharmaceutical will pay Tianjin Boda the corresponding marketing service fees as stipulated in the agreement. The agreement is valid until March 31, 2026 (initial term); before the expiration of the initial term, both parties may negotiate renewal matters, and if the conditions stipulated in the agreement are met, it will automatically renew for two years until March 31, 2028.

The Mecobalamin Injection (trade name: MicoCare) promoted by Tianjin Boda is an original research drug, with a specification of 1ml:0.5mg per vial, indicated for peripheral neuropathy and treatment of megaloblastic anemia due to vitamin B12 deficiency.

It is reported that this matter will further enrich the company's product pipeline, expected to increase the company's operating income and profits; it will help enhance the company's specialized academic promotion capabilities and lay the foundation for more product collaborations in the future